Anti-tumor and anti-metastatic effects of RRx-001 on hepatocellular carcinoma: mechanisms of action and therapeutic potential
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.1-Bromoacetyl-3,3-dinitroazetidine (RRx-001) effectively inhibits hepatocellular carcinoma (HCC) cell growth and spread by inducing apoptosis. This novel compound may work by altering CD47 and TP53 protein levels, offering a promising new cancer therapy.
Area Of Science
- Oncology
- Molecular Biology
- Pharmacology
Background
- 1-Bromoacetyl-3,3-dinitroazetidine (RRx-001) exhibits significant antitumor properties, suggesting its therapeutic potential in oncology.
- Hepatocellular carcinoma (HCC) remains a major global health challenge, necessitating the development of novel therapeutic strategies.
Purpose Of The Study
- To investigate the efficacy of RRx-001 against hepatocellular carcinoma (HCC) cell lines.
- To elucidate the molecular mechanisms underlying RRx-001's anti-cancer effects in HCC.
Main Methods
- Cell viability, migration, and invasion assays were performed on HCC cell lines (Huh7, Hepa1-6, MHCC97H) treated with RRx-001.
- Apoptosis assays and RNA sequencing were employed to analyze cellular responses and gene expression changes.
- Western blot analysis assessed CD47 and TP53 protein levels, and a xenograft mouse model evaluated in vivo efficacy.
Main Results
- RRx-001 significantly inhibited HCC cell viability, migration, and invasion in vitro.
- The compound induced apoptosis in HCC cells, with effects potentially linked to CD47 downregulation and TP53 upregulation.
- In vivo studies confirmed that RRx-001 effectively suppressed tumor growth in a xenograft mouse model.
Conclusions
- RRx-001 demonstrates potent anti-HCC activity by reducing cell viability and inducing apoptosis.
- The observed therapeutic effects are potentially mediated by the modulation of CD47 and TP53 signaling pathways.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...